IL1B and metabolic dysfunction-associated steatotic liver disease: We have shown that obese MASLD patients with insulin resistance display very high levels of IL-1β in the adipose tissue (both subcutaneous and visceral adipose tissue), with levels massively exceeding their liver expression, and successful weight loss almost eliminated IL-1β expression in the subcutaneous adipose tissue [30].